Anzeige
Mehr »
Samstag, 31.05.2025 - Börsentäglich über 12.000 News
Könnte diese Penny-Aktie das nächste 12 € Perpetua werden?! Verpassen Sie nicht den Antimon-Boom!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H81X | ISIN: SE0010573113 | Ticker-Symbol: 7ZA
Frankfurt
30.05.25 | 08:03
0,325 Euro
+0,15 % +0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASCELIA PHARMA AB Chart 1 Jahr
5-Tage-Chart
ASCELIA PHARMA AB 5-Tage-Chart

Aktuelle News zur ASCELIA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.05.Ascelia Pharma: Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission249MALMÖ, SE / ACCESS Newswire / May 16, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2025 (January - March), which is now available...
► Artikel lesen
07.05.Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025242MALMÖ, SE / ACCESS Newswire / May 7, 2025 / Ascelia Pharma (STO:ACE) - Today, on 7 May 2025, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below.Resolution...
► Artikel lesen
30.04.Change in Number of Shares and Votes in Ascelia Pharma AB188MALMÖ, SE / ACCESS Newswire / April 30, 2025 / Ascelia Pharma (STO:ACE)During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the exercise...
► Artikel lesen
16.04.Ascelia Pharma AB: Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1207NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE...
► Artikel lesen
11.04.Ascelia Pharma: Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion267MALMÖ, SE / ACCESS Newswire / April 11, 2025 / Ascelia Pharma (STO:ACE):The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation...
► Artikel lesen
08.04.Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology278MALMÖ, SE / ACCESS Newswire / April 8, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions,...
► Artikel lesen
ASCELIA PHARMA Aktie jetzt für 0€ handeln
04.04.Notice of Annual General Meeting in Ascelia Pharma AB321The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April...
► Artikel lesen
04.04.Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference182MALMÖ, SE / ACCESS Newswire / April 4, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions,...
► Artikel lesen
31.03.The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025312NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE...
► Artikel lesen
18.03.Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025454MALMÖ, SE / ACCESS Newswire / March 18, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) , a biotech focused on improving the life of people living with rare cancer conditions, today announced...
► Artikel lesen
25.02.Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025173MALMÖ, SE / ACCESS Newswire / February 25, 2025 / Ascelia Pharma (STO:ACE) Today, on 25 February 2025, an extraordinary general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions...
► Artikel lesen
12.02.Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB326MALMO, SWEDEN / ACCESS Newswire / February 12, 2025 / Ascelia Pharma (STO:ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 7 May 2025 has been...
► Artikel lesen
07.02.Ascelia Pharma: Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study264MALMÖ, SWEDEN / ACCESS Newswire / February 7, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today published its Q4 and Full Year Report for 2024 (January - December), which...
► Artikel lesen
30.01.Notice of Extraordinary General Meeting in Ascelia Pharma AB316The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / January...
► Artikel lesen
27.01.Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting196MALMÖ, SE / ACCESSWIRE / January 27, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today...
► Artikel lesen
23.12.24Ascelia Pharma Patent Granted in China for Second Generation Orviglance525MALMÖ, SWEDEN / ACCESSWIRE / December 23, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions...
► Artikel lesen
17.12.24Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025313MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abstracts...
► Artikel lesen
29.11.24Change in Number of Shares and Votes in Ascelia Pharma AB436MALMÖ, SE / ACCESSWIRE / November 29, 2024 / Ascelia Pharma (STO:ACE)During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 26...
► Artikel lesen
22.11.24Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program425MALMÖ, SWEDEN / ACCESSWIRE / November 22, 2024 / Ascelia Pharma (STO:ACE) The board of directors of Ascelia Pharma AB ("Ascelia Pharma") has on 22 November 2024 resolved to convert 26,310 series C shares...
► Artikel lesen
07.11.24Ascelia Pharma AB: Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025236Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q3 for 2024 (January - September), which is now available on the company's website: https://www.ascelia.com/ir-media/financial-reports/KEY...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1